Cara Therapeutics Inc (NASDAQ:CARA) had its price target reduced by Cantor Fitzgerald from $26.00 to $25.00 in a report published on Friday. They currently have an overweight rating on the biopharmaceutical company’s stock.
Other equities analysts have also issued research reports about the stock. HC Wainwright set a $22.00 target price on shares of Cara Therapeutics and gave the company a buy rating in a report on Wednesday, February 22nd. Janney Montgomery Scott set a $20.00 target price on shares of Cara Therapeutics and gave the company a buy rating in a report on Saturday, March 11th. Canaccord Genuity reaffirmed a buy rating and set a $25.00 target price on shares of Cara Therapeutics in a report on Friday, March 10th. Laidlaw increased their target price on shares of Cara Therapeutics from $17.00 to $20.00 and gave the company a buy rating in a report on Friday, March 10th. Finally, Vetr raised shares of Cara Therapeutics from a hold rating to a buy rating and set a $18.44 target price on the stock in a report on Wednesday, April 5th. Two research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company. Cara Therapeutics has a consensus rating of Buy and a consensus target price of $25.89.
Cara Therapeutics (NASDAQ:CARA) opened at 15.59 on Friday. Cara Therapeutics has a one year low of $4.35 and a one year high of $20.90. The stock’s 50 day moving average is $16.84 and its 200-day moving average is $13.53. The firm’s market cap is $506.78 million.
Cara Therapeutics (NASDAQ:CARA) last released its earnings results on Thursday, May 4th. The biopharmaceutical company reported ($0.81) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.73) by $0.08. The company had revenue of $0.91 million for the quarter, compared to the consensus estimate of $0.11 million. During the same quarter in the prior year, the company posted ($0.39) earnings per share. The business’s revenue was up 12900.0% compared to the same quarter last year. On average, equities research analysts expect that Cara Therapeutics will post ($2.35) earnings per share for the current fiscal year.
In related news, major shareholder Ventures Vi Lp Rho bought 500,000 shares of the company’s stock in a transaction dated Friday, March 31st. The stock was purchased at an average cost of $18.19 per share, with a total value of $9,095,000.00. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 7.70% of the company’s stock.
Large investors have recently bought and sold shares of the company. Teachers Advisors LLC boosted its stake in Cara Therapeutics by 8.3% in the fourth quarter. Teachers Advisors LLC now owns 33,390 shares of the biopharmaceutical company’s stock valued at $310,000 after buying an additional 2,552 shares in the last quarter. Chescapmanager LLC bought a new stake in Cara Therapeutics during the fourth quarter valued at approximately $6,365,000. Flinton Capital Management LLC bought a new stake in Cara Therapeutics during the fourth quarter valued at approximately $139,000. Disciplined Growth Investors Inc. MN bought a new stake in Cara Therapeutics during the fourth quarter valued at approximately $8,251,000. Finally, Elkfork Partners LLC bought a new stake in Cara Therapeutics during the fourth quarter valued at approximately $296,000. 43.29% of the stock is owned by hedge funds and other institutional investors.
Cara Therapeutics Company Profile
Cara Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. It is developing a class of product candidates that target the body’s peripheral nervous system.
What are top analysts saying about Cara Therapeutics Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Cara Therapeutics Inc and related companies.